You are here

microRNA profiling for diagnosis and prognosis in canine multicentric lymphoma

** PLEASE NOTE THAT THIS STUDY IS NO LONGER RECRUITING PATIENTS **

Objective:

The purpose of this study is to determine how the microRNA profile in newly diagnosed dogs with multicentric lymphoma is different from healthy dogs. We also aim to determine what changes in the microRNA profile occur during CHOP therapy, and how these changes correlate with response to therapy, length of remission, and overall survival.

Background:

Lymphoma is one of the most common cancers in dogs and cats. It comprises 7 to 24% of all canine cancers, with an increasing incidence rate. A similar trend is present in humans, for whom non-Hodgkin’s lymphoma represents 5% of all new cancer cases, the fifth leading cause of cancer deaths, and the second fastest growing cancer in terms of mortality.

Standard treatment of lymphoma in dogs and humans integrates a multi-agent chemotherapy protocol called CHOP. However, response to therapy can vary widely between patients. A recent interest in identifying molecular profiles to better predict a patients’ response to therapy and prognosis has led researchers to investigate the usefulness of microRNA’s. MicroRNA’s are small molecules that play key roles in regulating gene expression.

Samples Required:

Blood sample (2-3ml) is required at every routine visit.

Inclusion criteria:

  • Diagnosis of multicentric lymphoma (cytology or histopathology);
  • Treatment with Madison-Wisconsin (CHOP) protocol to take place at OVC;
  • No previous chemotherapy treatment (e.g. with L-aspar).

Client Compensation:

No cost to owner to participate in the study.

Researchers:

  • Dr. Darren Wood (co-PI)
  • Dr. Geoff Wood (co-PI)
  • Dr. Karlee Craig

For further information please contact:

Vicky Sabine (PhD), Clinical Research Co-ordinator

Funded by OVC Pet Trust and Canadian Kennel Club Foundation